epocrates logo
epocrates logo
epocrates logo
  • 0

Interaction Check

epocrates logo

Sign in to access our clinical decision support tools

Sign in Create Account

Selected Drugs Clear All

  • remove Avastin
    bevacizumab
  • remove Genvoya
    elvitegravir/ cobicistat/ emtricitabine/ tenofovir alafenamide
  • remove Ruxience (rituximab-pvvr)
    rituximab

multicheck MultiCheck Results - 3 Interactions

Smiley face Smiley face

Monitor/Modify Tx

Smiley face Smiley face Avastin (bevacizumab) + Genvoya (elvitegravir/ cobicistat/ emtricitabine/ tenofovir alafenamide)

Monitor/Modify Tx


bevacizumab + tenofovir alafenamide

monitor renal fxn: combo may incr. tenofovir levels, risk of nephrotoxicity, other adverse effects (additive effects)

Smiley face Smiley face Avastin (bevacizumab) + Ruxience (rituximab-pvvr) (rituximab)

Monitor/Modify Tx


bevacizumab + rituximab

monitor CBC, renal fxn: combo may incr. risk of myelosuppression, nephrotoxicity (additive effects)

Smiley face Smiley face Genvoya (elvitegravir/ cobicistat/ emtricitabine/ tenofovir alafenamide) + Ruxience (rituximab-pvvr) (rituximab)

Monitor/Modify Tx


tenofovir alafenamide + rituximab

monitor renal fxn: combo may incr. tenofovir levels, risk of nephrotoxicity, other adverse effects (additive effects)

Additional Considerations

Smiley face Smiley face tenofovir alafenamide in Genvoya

tenofovir alafenamide (prodrug) converted to tenofovir

Help
FDA Reporting Form
 
Download Epocrates from the App Store Download Epocrates from the Play Store
About Us Features Business Solutions Help & Feedback
© 2026 epocrates, Inc.    Terms of Use Privacy Policy Editorial Policy Do Not Sell or Share My Information